Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis
- PMID: 31994476
- DOI: 10.1017/S0033291719003519
Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis
Abstract
Background: Recent evidence suggests that cannabidiol (CBD), a non-intoxicating ingredient present in cannabis extract, has an antipsychotic effect in people with established psychosis. However, the effect of CBD on the neurocognitive mechanisms underlying psychosis is unknown.
Methods: Patients with established psychosis on standard antipsychotic treatment were studied on separate days at least one week apart, to investigate the effects of a single dose of orally administered CBD (600 mg) compared to a matched placebo (PLB), using a double-blind, randomized, PLB-controlled, repeated-measures, within-subject cross-over design. Three hours after taking the study drug participants were scanned using a block design functional magnetic resonance imaging (fMRI) paradigm, while performing a verbal paired associate learning task. Fifteen psychosis patients completed both study days, 13 completed both scanning sessions. Nineteen healthy controls (HC) were also scanned using the same fMRI paradigm under identical conditions, but without any drug administration. Effects of CBD on brain activation measured using the blood oxygen level-dependent hemodynamic response fMRI signal were studied in the mediotemporal, prefrontal, and striatal regions of interest.
Results: Compared to HC, psychosis patients under PLB had altered prefrontal activation during verbal encoding, as well as altered mediotemporal and prefrontal activation and greater mediotemporal-striatal functional connectivity during verbal recall. CBD attenuated dysfunction in these regions such that activation under its influence was intermediate between the PLB condition and HC. CBD also attenuated hippocampal-striatal functional connectivity and caused trend-level symptom reduction in psychosis patients.
Conclusions: This suggests that normalization of mediotemporal and prefrontal dysfunction and mediotemporal-striatal functional connectivity may underlie the antipsychotic effects of CBD.
Keywords: Cannabidiol; cannabinoid; fMRI; functional connectivity; memory; psychosis; schizophrenia.
Similar articles
-
Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.JAMA Psychiatry. 2018 Nov 1;75(11):1107-1117. doi: 10.1001/jamapsychiatry.2018.2309. JAMA Psychiatry. 2018. PMID: 30167644 Free PMC article. Clinical Trial.
-
Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis.Arch Gen Psychiatry. 2009 Apr;66(4):442-51. doi: 10.1001/archgenpsychiatry.2009.17. Arch Gen Psychiatry. 2009. PMID: 19349314 Clinical Trial.
-
Induction of psychosis by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing.Arch Gen Psychiatry. 2012 Jan;69(1):27-36. doi: 10.1001/archgenpsychiatry.2011.161. Arch Gen Psychiatry. 2012. PMID: 22213786
-
A systematic review of the antipsychotic properties of cannabidiol in humans.Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Schizophr Res. 2015. PMID: 25667194 Review.
-
Cannabinoids, reward processing, and psychosis.Psychopharmacology (Berl). 2022 May;239(5):1157-1177. doi: 10.1007/s00213-021-05801-2. Epub 2021 Mar 1. Psychopharmacology (Berl). 2022. PMID: 33644820 Free PMC article. Review.
Cited by
-
Cannabidiol and brain function: current knowledge and future perspectives.Front Pharmacol. 2024 Jan 15;14:1328885. doi: 10.3389/fphar.2023.1328885. eCollection 2023. Front Pharmacol. 2024. PMID: 38288087 Free PMC article. Review.
-
Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies.Neural Regen Res. 2024 Apr;19(4):788-799. doi: 10.4103/1673-5374.382220. Neural Regen Res. 2024. PMID: 37843213 Free PMC article. Review.
-
The therapeutic potential of purified cannabidiol.J Cannabis Res. 2023 Jun 13;5(1):21. doi: 10.1186/s42238-023-00186-9. J Cannabis Res. 2023. PMID: 37312194 Free PMC article. Review.
-
[Use of psychoactive substances as a treatment for psychosis].Rev Neurol. 2023 Jun 1;76(11):361-370. doi: 10.33588/rn.7611.2023077. Rev Neurol. 2023. PMID: 37231549 Free PMC article. Review. Spanish.
-
Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety.Psychiatry Res Commun. 2022 Dec;2(4):100074. doi: 10.1016/j.psycom.2022.100074. Epub 2022 Sep 13. Psychiatry Res Commun. 2022. PMID: 36875967 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
